Lactadherin inhibits secretory phospholipase A2 activity on pre-apoptotic leukemia cells

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Dokumenter

DOI

  • Steffen Nyegaard, Danmark
  • Valerie A. Novakovic, Departments of Medicine, Veterans Administration Boston Healthcare System, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusett, USA
  • Jan Trige Rasmussen
  • Gary E Gilbert, Departments of Medicine, Veterans Administration Boston Healthcare System, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA
Secretory phospholipase A2 (sPLA2) is a critical component of insect and snake venoms and is secreted by mammalian leukocytes during inflammation. Elevated secretory PLA2 concentrations are associated with autoimmune diseases and septic shock. Many sPLA2’s do not bind to plasma membranes of quiescent cells but bind and digest phospholipids on the membranes of stimulated or apoptotic cells. The capacity of these phospholipases to digest membranes of stimulated or apoptotic cells correlates to the exposure of phosphatidylserine. In the present study, the ability of the phosphatidyl-L-serine-binding protein, lactadherin to inhibit phospholipase enzyme activity has been assessed. Inhibition of human secretory phospholipase A2-V on phospholipid vesicles exceeded 90%, whereas inhibition of Naja mossambica sPLA2 plateaued at 50–60%. Lactadherin inhibited 45% of activity of Naja mossambica sPLA2 and >70% of human secretory phospholipase A2-V on the membranes of human NB4 leukemia cells treated with calcium ionophore A23187. The data indicate that lactadherin may decrease inflammation by inhibiting sPLA2
OriginalsprogEngelsk
Artikelnummer e77143
TidsskriftP L o S One
Vol/bind8
Nummer10
Sider (fra-til)1-9
Antal sider9
ISSN1932-6203
DOI
StatusUdgivet - 23 okt. 2013

Se relationer på Aarhus Universitet Citationsformater

Download-statistik

Ingen data tilgængelig

ID: 68893598